Sionna Therapeutics raises $182M in Series C financing for cystic fibrosis drug development.
Sionna Therapeutics, a clinical-stage biotech firm, raised $182M in Series C financing to advance its experimental cystic fibrosis drugs, aiming to compete with market leader Vertex Pharmaceuticals. The funds will be used for clinical development of small molecules targeting the CFTR protein's first nucleotide-binding domain (NBD1), crucial for restoring function. Sionna plans to have four compounds in clinical trials by 2024.
March 06, 2024
3 Articles